Surface Oncology Highlights New SRF388 Data At AACR Meeting

Surface Oncology Inc SURF announced the presentation of new preclinical and translational data for SRF388, a first-in-class antibody targeting IL-27, at the American Association for Cancer Research (AACR) Annual Meeting 2022.

  • Pharmacokinetics (PK) from the dose-escalation phase of the SRF388 Phase 1 study were linear, with no dose-limiting toxicities reported.
  • The concentration of SRF388 associated with optimal antitumor activity in a preclinical mouse model was approximately 20-fold above the concentration needed to inhibit whole blood phosphorylated STAT1 completely.
  • The concentration of SRF388 was reached and exceeded in patients at a 10 mg/kg dose. One patient with squamous non-small-cell lung cancer experienced a confirmed partial response at this dose.
  • SRF388 translational data supports the recommended Phase 2 monotherapy dose selection of 10 mg/kg administered intravenously every four weeks.
  • The efficacy of adding IL-27 blockade with SRF388 to atezolizumab/bevacizumab in treatment-naïve HCC is also being explored in a Phase 2 study.
  • Price Action: SURF shares are down 2.17% at $2.71 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsPreclinical Phase
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!